We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No P/E, the company is not profitable on a trailing basis.
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save SOLARA.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
